Alnylam Pharmaceuticals (ALNY)
NASDAQ:ALNY
Want to see ALNY full AI Analyst Report?
Earnings Data
Report Date
Jul 30, 2026Before Open (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
1.58Last Year’s EPS
-0.51Same Quarter Last Year
Strong Buy
Based on 20 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call presented a strong commercial and financial quarter highlighted by record product revenues, robust TTR franchise growth, profitability and substantial pipeline progress including accelerated Phase III enrollment and supportive real-world evidence. Challenges noted were margin pressure from rising royalties, higher R&D/SG&A investments, an expected Germany pricing adjustment that transiently impacted international results, and typical seasonal/operational phasing headwinds. Management reiterated full-year guidance and communicated confidence in ongoing launch dynamics and pipeline execution, while acknowledging competitive and timing uncertainties.Company Guidance
Record Quarterly Product Revenues
Combined net product revenues of $1.036 billion in Q1 2026 — the company's first quarter exceeding $1 billion; +121% year-over-year and +4% sequentially versus Q4 2025.
TTR Franchise Momentum
Global TTR net revenues of $910 million in Q1 2026; +153% year-over-year and +6% quarter-over-quarter. U.S. TTR revenues grew ~9% vs Q4 and >230% year-over-year, with $59 million U.S. revenue growth over Q4 despite seasonal shipping and reauthorization dynamics.
Strong Rare Disease and Royalty Performance
Rare disease net revenues of $126 million, +15% year-over-year. Royalty revenues of $49 million, up 85% year-over-year driven by higher global LEQVIO sales.
Profitability and Cash Position
Non-GAAP operating income of $339 million — more than 4x increase year-over-year. Third consecutive quarter of both GAAP and non-GAAP profitability. Cash, cash equivalents and marketable securities of $3.0 billion (up from $2.9 billion at year-end 2025).
Pipeline Progress and Clinical Momentum
More than 25 clinical programs in development. Initiated Phase I trial of ALN-2232 (adipose-directed RNAi). Presented impactful vutrisiran and zilebesiran data at ACC. Advanced nucresiran TRITON-CM Phase III with enrollment accelerating and protocol expansion from ~1,250 to ~1,750 patients.
Real-World Evidence Supporting Vutrisiran
Retrospective real-world data (~4 years) showing >93% adherence to vutrisiran (>=80% days covered) and >85% persistence at >1 year. HELIOS-B post-hoc analyses showed vutrisiran reduced risk of worsening diastolic dysfunction and lowered all-cause mortality and cardiovascular events irrespective of baseline DDG.
Commercial Execution and Prescriber Expansion
More than 1,200 unique new U.S. prescribers since last March. Adherence for AMVUTTRA exceeded 90% and first-line access coverage over 90% with most patients facing $0 out-of-pocket; international reimbursement wins and AMVUTTRA launches in Austria, U.K., Switzerland, Italy and strong execution in Japan.
Reiterated 2026 Guidance and Strategic Vision
Reiterated full-year guidance (including $4.4B–$4.7B TTR product sales expectation) and reiterated Alnylam 2030 strategic goals: deliver ≥2 transformative medicines beyond TTR, RNAi delivery to ≥10 tissue types, >40 programs in clinic by 2030 and invest ~30% of revenues in non-GAAP R&D across the period.
ALNY Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
ALNY Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Apr 30, 2026 | $301.19 | $309.49 | +2.76% |
Feb 12, 2026 | $322.28 | $308.48 | -4.28% |
Oct 30, 2025 | $481.59 | $449.56 | -6.65% |
Jul 31, 2025 | $339.80 | $392.24 | +15.43% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Alnylam Pharmaceuticals (ALNY) report earnings?
Alnylam Pharmaceuticals (ALNY) is schdueled to report earning on Jul 30, 2026, Before Open (Confirmed).
What is Alnylam Pharmaceuticals (ALNY) earnings time?
Alnylam Pharmaceuticals (ALNY) earnings time is at Jul 30, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ALNY EPS forecast?
ALNY EPS forecast for the fiscal quarter 2026 (Q2) is 1.58.